FY2023 Earnings Forecast for Immunic, Inc. (NASDAQ:IMUX) Issued By Leerink Partnrs

Immunic, Inc. (NASDAQ:IMUXFree Report) – Equities research analysts at Leerink Partnrs issued their FY2023 earnings per share estimates for Immunic in a research note issued on Monday, February 5th. Leerink Partnrs analyst T. Smith anticipates that the company will post earnings per share of ($2.19) for the year. The consensus estimate for Immunic’s current full-year earnings is ($2.13) per share. Leerink Partnrs also issued estimates for Immunic’s Q4 2023 earnings at ($0.56) EPS, Q1 2024 earnings at ($0.36) EPS, Q2 2024 earnings at ($0.26) EPS, Q3 2024 earnings at ($0.28) EPS, Q4 2024 earnings at ($0.27) EPS, FY2024 earnings at ($1.16) EPS, FY2025 earnings at ($0.91) EPS, FY2026 earnings at ($0.99) EPS and FY2027 earnings at ($0.90) EPS.

Immunic (NASDAQ:IMUXGet Free Report) last posted its quarterly earnings data on Tuesday, November 14th. The company reported ($0.51) EPS for the quarter, topping analysts’ consensus estimates of ($0.55) by $0.04.

Separately, Wedbush reaffirmed an “outperform” rating and set a $7.00 price objective on shares of Immunic in a report on Tuesday, November 14th.

View Our Latest Stock Report on Immunic

Immunic Stock Down 2.4 %

NASDAQ IMUX opened at $1.21 on Thursday. The stock’s 50 day moving average is $1.29 and its two-hundred day moving average is $1.41. Immunic has a 1-year low of $0.95 and a 1-year high of $3.11.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of the company. RTW Investments LP raised its position in Immunic by 0.9% in the 3rd quarter. RTW Investments LP now owns 4,335,255 shares of the company’s stock worth $6,373,000 after purchasing an additional 40,796 shares during the last quarter. Gratus Capital LLC boosted its stake in shares of Immunic by 15.1% during the 4th quarter. Gratus Capital LLC now owns 1,941,454 shares of the company’s stock worth $2,912,000 after buying an additional 254,999 shares during the last quarter. BlackRock Inc. boosted its stake in shares of Immunic by 0.9% during the 1st quarter. BlackRock Inc. now owns 1,314,484 shares of the company’s stock worth $14,853,000 after buying an additional 11,708 shares during the last quarter. Vanguard Group Inc. boosted its stake in shares of Immunic by 13.2% during the 3rd quarter. Vanguard Group Inc. now owns 994,671 shares of the company’s stock worth $3,143,000 after buying an additional 115,649 shares during the last quarter. Finally, Acadian Asset Management LLC boosted its stake in shares of Immunic by 26.8% during the 3rd quarter. Acadian Asset Management LLC now owns 757,250 shares of the company’s stock worth $1,111,000 after buying an additional 159,973 shares during the last quarter. Institutional investors own 45.26% of the company’s stock.

Immunic Company Profile

(Get Free Report)

Immunic, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. Its lead development program is IMU-838, which is in Phase 3 clinical for treatment of multiple sclerosis, including relapsing multiple sclerosis and other chronic inflammatory and autoimmune diseases, as well as to treat coronavirus disease.

See Also

Earnings History and Estimates for Immunic (NASDAQ:IMUX)

Receive News & Ratings for Immunic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunic and related companies with MarketBeat.com's FREE daily email newsletter.